Brief: Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors
30/06/2025 13:15
Revolution Medicines Inc RVMD.O: REVOLUTION MEDICINES AND SUMMIT THERAPEUTICS ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF THREE RAS(ON) INHIBITORS WITH IVONESCIMAB IN RAS MUTANT TUMORS REVOLUTION MEDICINES INC - SUMMIT TO SUPPLY IVONESCIMAB, REVOLUTION MEDICINES TO SPONSOR STUDY Source text: ID:nGNX8PWjNv Further company coverage: RVMD.O
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)